Prosecution Insights
Last updated: April 19, 2026

Examiner: FAY, ZOHREH ALEMZADEH

Tech Center 1600 • Art Units: 1612 1617 1621 1627 1629

This examiner grants 52% of resolved cases

Performance Statistics

51.5%
Allow Rate
-8.5% vs TC avg
1161
Total Applications
-6.7%
Interview Lift
1174
Avg Prosecution Days
Based on 1094 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
12.0%
§102 Novelty
50.7%
§103 Obviousness
20.2%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17777478 IONIC LIQUIDS FOR DRUG DELIVERY Final Rejection PRESIDENT AND FELLOWS OF HARVARD COLLEGE
18011399 REDOX-RESPONSIVE NANOPARTICLE COMPOSITIONS FOR OCULAR DELIVERY OF THERAPEUTICS Non-Final OA OHIO STATE INNOVATION FOUNDATION
17392837 CONSISTENCY OF CROP YIELD THROUGH BIOLOGICAL NITROGEN FIXATION Non-Final OA Pivot Bio, Inc.
19000196 GEL BASE COMPOSITION FOR COMPOUNDING INTO A MUCOADHESIVE DELIVERY SYSTEM Non-Final OA MEDISCA PHARMACEUTIQUE Inc.
17760990 HIGH DENSITY LIPOPROTEIN-LIKE NANOPARTICLES AS INDUCERS OF FERROPTOSIS IN CANCER Non-Final OA Northwestern University
17975485 COMPOSITIONS, ARTICLES, DEVICES, AND METHODS RELATED TO DROPLETS COMPRISING A CLOAKING FLUID Non-Final OA Massachusetts Institute of Technology
17640128 USE OF ENCAPSULATED STEROLS TO MODIFY GROWTH OF CROPS, CONTROL, AGRICULTURAL PESTS AND AS NON-TOXIC PRE-EMERGENT HERBICIDES Non-Final OA The Texas A&M University System
19189086 RISANKIZUMAB COMPOSITIONS Final Rejection ABBVIE INC.
17800838 SUPRACHOROIDAL DELIVERY OF DRUG PARTICLES TO REDUCE TOXICITY Final Rejection The Johns Hopkins University
18025037 Medium for Tissue for Transplantation Non-Final OA Riken
17909601 STABILIZATION OF COMPOUNDS AS CYCLODEXTRIN COMPLEXES Final Rejection University of Pittsburgh - Of the Commonwealth System of Higher Education
17849545 BIOMIMETIC POLYMERIC COMPOSITE FOR HEART VALVE REPAIR Non-Final OA THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
18823760 NOVEL FORMULATION AND TREATMENT METHODS Non-Final OA PRODRUGXTEND PTY LTD
18281381 COSMETIC SKIN CARE COMPOSITION Non-Final OA Conopco, Inc., d/b/a UNILEVER
18578843 PHARMACEUTICAL COMPOSITIONS OF OZANIMOD Non-Final OA ZYDUS LIFESCIENCES LIMITED
18033689 OCULAR IMPLANT CONTAINING AN ACTIVE INGREDIENT Final Rejection OCULAR THERAPEUTIX, INC.
18018108 Aqueous Composition Final Rejection Rohto Pharmaceutical Co., Ltd.
18681706 OPHTHALMIC COMPOSITION FOR THE TREATMENT OF VISUAL DISORDERS Final Rejection FOODVICA, S.A. DE C.V.
18294487 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING HYPERHIDROSIS Non-Final OA Wayne Stephen ANDREWS
18576610 ORAL COMPLEX TABLET COMPRISING SITAGLIPTIN, DAPAGLIFLOZIN, AND METFORMIN Non-Final OA HANMI PHARM. CO., LTD.
18574889 SEED UNIT COMPRISING CHARCOAL AND POLYMERIC SUPERABSORBENT Non-Final OA Schierbecker Handels GmbH & Co. KG
18397155 PLANT BIOLOGIC INCLUDING PYRROLOQUINOLINE QUINONE (PQQ) Non-Final OA Dakota Bio LLC
18573953 COMPOSITIONS AND METHODS FOR VISION IMPROVEMENT Non-Final OA Azura Ophthalmics Ltd.
18543825 MULTIFUNCTIONAL AGRICULTURAL ADJUVANT COMPOSITIONS Non-Final OA WinField Solutions, LLC
18571711 COMPOUND LIQUID FERTILIZER Non-Final OA Albert Nikolaevich DENISOV
18007119 LYOPHILIZED FORMULATION CONTAINING CEPHALOSPORIN HAVING CATECHOL GROUP AND THE MANUFACTURING METHOD Final Rejection SHIONOGI & CO., LTD.
18560787 EXTENDED-WEAR SILICONE HYDROGEL CONTACT LENSES AND USES THEREOF Non-Final OA OCUMEDIC, INC.
18284284 LAQUINIMOD FORMULATION FOR OCULAR USE Final Rejection ACTIVE BIOTECH AB
18280778 Multi-Dose Container for Ophthalmic Compositions Non-Final OA Vyluma Inc.
18000937 BIODEGRADABLE COMPOSITIONS AND IMPLANTS Non-Final OA RE-VANA THERAPEUTICS LTD

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month